IBA SA - basic data - update following capital increase dated 22 avril 2016
22 Avril 2016 - 12:00PM
IBA -
Data concerning transparency
Louvain-la-Neuve,
Belgium, April 22, 2016 - IBA (Ion Beam Applications SA), the
world's leading provider of proton therapy solutions for the
treatment of cancer, communicates today the basic and additional
data as per Article 15 §1 al.1 of the Transparency Law, following
its capital increase (further to exercises of stock options) dated
April 22, 2016.
Data concerning
transparency
Heading II of the law of May 2, 2007 and the Royal
Decree of February 14, 2008
Communication of the basic data as per Article 15
§1 al.1 of the Law
-
Total capital:
EUR 41 437 985.59
-
Total number of securities conferring the voting
right:
29 523 884 (of which 12 702 489 with VVPR
strips)
-
Total number of voting rights (= the
denominator):
29 523 884
-
Total number of securities conferring the voting
right, by category: N/A
-
Total number of voting rights, by
category:
N/A
Communication of the additional data as per
Article 15 §1 al.2 of the Law
-
Total number of convertible bonds conferring the
voting right:
0
-
Total number of rights, materialized or not by
certificates, giving the
right to subscribe to newly issued securities conferring the voting
right
(e.g.
warrants):
863 495
-
Total number of voting rights which would result
from the exercise of
these conversion or subscription
rights:
863 495
-
Total number of shares without voting right:
0
Statutory thresholds as per Article 18 of the
Law
The applicable thresholds as follows: three
percent, five percent, ten percent, fifteen percent and so on by
brackets of five percent.
*
*
*
*
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The Company is the worldwide
technology leader in the field of proton therapy, the most advanced
form of radiation therapy available today. IBA's proton therapy
solutions are flexible and adaptable, allowing customers to choose
from universal full scale proton therapy centers as well as
compact, single room systems. In addition, IBA also has a radiation
dosimetry business and develops particle accelerators for the
medical world and industry.
Headquartered in Belgium and
employing about 1200 people worldwide, IBA has installed systems
across the world, from Europe and the US and to the emerging
markets. IBA is listed on the pan-European stock exchange EURONEXT.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information
can be found at: www.iba-worldwide.com
For more
information, please contact
IBA
Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com
20160422 evolution of the basic
data EN
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
HUG#2005921
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024